{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:29:24Z","timestamp":1779888564556,"version":"3.53.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BJC Rep"],"DOI":"10.1038\/s44276-025-00201-x","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T13:44:55Z","timestamp":1770126295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Obesity, metformin prescription and risk of advanced prostate cancer in non-diabetic men"],"prefix":"10.1038","volume":"4","author":[{"given":"Visalini","family":"Nair-Shalliker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rani","family":"Radhika-Chand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Chiam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish I","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry R.","family":"Greenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"201_CR1","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J, Feng F, Gillessen S, Ali SA, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet (London, England). 2024;403:1683\u2013722.","journal-title":"Lancet (London, England)"},{"key":"201_CR2","doi-asserted-by":"publisher","first-page":"e537","DOI":"10.1016\/S2468-2667(22)00090-1","volume":"7","author":"Q Luo","year":"2022","unstructured":"Luo Q, O\u2019Connell DL, Yu XQ, Kahn C, Caruana M, Pesola F, et al. Cancer incidence and mortality in Australia from 2020 to 2044 and an exploratory analysis of the potential effect of treatment delays during the COVID-19 pandemic: a statistical modelling study. The Lancet Public health. 2022;7:e537\u2013e48.","journal-title":"The Lancet Public health"},{"key":"201_CR3","doi-asserted-by":"publisher","first-page":"236","DOI":"10.6004\/jnccn.2023.0014","volume":"21","author":"KA Moses","year":"2023","unstructured":"Moses KA, Sprenkle PC, Bahler C, Box G, Carlsson SV, Catalona WJ, et al. NCCN Guidelines\u00ae Insights: Prostate Cancer Early Detection, Version 1.2023: Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2023;21:236\u201346.","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"201_CR4","unstructured":"https:\/\/www.urologyhealth.org\/urology-a-z\/a_\/advanced-prostate-cancer."},{"key":"201_CR5","unstructured":"World Cancer Research Fund -Diet N, Physical activity and Prodtate cancer- Continuous Update Project. https:\/\/www.wcrf.org\/sites\/default\/files\/Prostate-Cancer-2014-Report.pdf. 2018."},{"key":"201_CR6","doi-asserted-by":"crossref","unstructured":"Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006;15:1977-83.","DOI":"10.1158\/1055-9965.EPI-06-0477"},{"key":"201_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/21681805.2016.1271353","volume":"51","author":"A Haring","year":"2017","unstructured":"Haring A, Murtola TJ, Talala K, Taari K, Tammela TL, Auvinen A. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Scandinavian journal of urology. 2017;51:5\u201312.","journal-title":"Scandinavian journal of urology"},{"key":"201_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/11795549231152073","volume":"17","author":"CS Lee","year":"2023","unstructured":"Lee CS, Lam SY, Liu A, Sison C, Zhu XH. A Retrospective Study of the Effect of Metformin on Patients with Metastatic Prostate Cancer. Clinical Medicine Insights Oncology. 2023;17:11795549231152073.","journal-title":"Clinical Medicine Insights Oncology"},{"key":"201_CR9","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1200\/JCO.2012.46.7043","volume":"31","author":"D Margel","year":"2013","unstructured":"Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31:3069\u201375.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"201_CR10","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.eururo.2014.04.027","volume":"66","author":"MA Preston","year":"2014","unstructured":"Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, et al. Metformin use and prostate cancer risk. European urology. 2014;66:1012\u201320.","journal-title":"European urology"},{"key":"201_CR11","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1093\/annonc\/mdr020","volume":"22","author":"XX He","year":"2011","unstructured":"He XX, Tu SM, Lee MH, Yeung SJ. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2011;22:2640\u20135.","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology"},{"key":"201_CR12","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1093\/aje\/kwn190","volume":"168","author":"TJ Murtola","year":"2008","unstructured":"Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Antidiabetic medication and prostate cancer risk: a population-based case-control study. American journal of epidemiology. 2008;168:925\u201331.","journal-title":"American journal of epidemiology"},{"key":"201_CR13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2337\/dc11-0857","volume":"35","author":"R Ruiter","year":"2012","unstructured":"Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes care. 2012;35:119\u201324.","journal-title":"Diabetes care"},{"key":"201_CR14","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s10552-009-9407-y","volume":"20","author":"JL Wright","year":"2009","unstructured":"Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer causes & control : CCC. 2009;20:1617\u201322.","journal-title":"Cancer causes & control : CCC"},{"key":"201_CR15","first-page":"604","volume":"83","author":"ME R\u00f8der","year":"1998","unstructured":"R\u00f8der ME, Porte D Jr, Schwartz RS, Kahn SE. Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. The Journal of clinical endocrinology and metabolism. 1998;83:604\u20138.","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"201_CR16","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ejca.2015.02.003","volume":"51","author":"T Nordstr\u00f6m","year":"2015","unstructured":"Nordstr\u00f6m T, Clements M, Karlsson R, Adolfsson J, Gr\u00f6nberg H. The risk of prostate cancer for men on aspirin, statin or antidiabetic medications. European journal of cancer (Oxford, England : 1990). 2015;51:725\u201333.","journal-title":"European journal of cancer (Oxford, England : 1990)"},{"key":"201_CR17","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.2337\/dc12-0788","volume":"35","author":"S Suissa","year":"2012","unstructured":"Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes care. 2012;35:2665\u201373.","journal-title":"Diabetes care"},{"key":"201_CR18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41391-024-00871-7","volume":"28","author":"Y Liu","year":"2025","unstructured":"Liu Y, Zhang Q, Huang X. Effect of metformin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from real-world studies. Prostate cancer and prostatic diseases. 2025;28:210\u20139.","journal-title":"Prostate cancer and prostatic diseases"},{"key":"201_CR19","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1007\/s00125-010-1804-y","volume":"53","author":"PD Home","year":"2010","unstructured":"Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia. 2010;53:1838\u201345.","journal-title":"Diabetologia"},{"key":"201_CR20","doi-asserted-by":"crossref","unstructured":"Fleshner NE, Bernardino RM, Izawa J, Drachenberg D, Saranchuk JW, Fairey A, et al. Metformin Active Surveillance Trial in Low-Risk Prostate Cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2025;43:3662\u201371.","DOI":"10.1200\/JCO-25-01070"},{"key":"201_CR21","doi-asserted-by":"publisher","first-page":"831.e1","DOI":"10.1016\/j.urolonc.2021.05.020","volume":"39","author":"R Alghandour","year":"2021","unstructured":"Alghandour R, Ebrahim MA, Elshal AM, Ghobrial F, Elzaafarany M, Elbaiomy MA. Repurposing metformin as anticancer drug: Randomized controlled trial in advanced prostate cancer (MANSMED). Urologic Oncology: Seminars and Original Investigations. 2021;39:831.e1\u2013e10.","journal-title":"Urologic Oncology: Seminars and Original Investigations"},{"key":"201_CR22","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.eururo.2016.07.015","volume":"70","author":"S Gillessen","year":"2016","unstructured":"Gillessen S, Gilson C, James N, Adler A, Sydes MR, Clarke N. Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform. European urology. 2016;70:906\u20138.","journal-title":"European urology"},{"key":"201_CR23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41568-020-0295-5","volume":"20","author":"EJ Gallagher","year":"2020","unstructured":"Gallagher EJ, LeRoith D. Hyperinsulinaemia in cancer. Nature Reviews Cancer. 2020;20:629\u201344.","journal-title":"Nature Reviews Cancer"},{"key":"201_CR24","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/s41416-023-02204-2","volume":"128","author":"SR Lord","year":"2023","unstructured":"Lord SR, Harris AL. Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?. British journal of cancer. 2023;128:958\u201366.","journal-title":"British journal of cancer"},{"key":"201_CR25","unstructured":"Gillessen S, Murphy L, James ND, Sachdeva A, El-Taji O, Abdel-Aty H, et al. Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol. The Lancet Oncology. 2025."},{"key":"201_CR26","doi-asserted-by":"crossref","unstructured":"Park J, Kim Ms, Boo Y-k. The Effect of Time-Restricted Eating on Metabolic Risk Factors for Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease in Overweight and Obese Adults: A Systematic Review and Meta-Analysis. Nutrition Reviews. 2025.","DOI":"10.1093\/nutrit\/nuaf181"},{"key":"201_CR27","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/jnci\/djae295","volume":"117","author":"RJ Smith Jr.","year":"2025","unstructured":"Smith RJ Jr., Zollo R, Kalvapudi S, Vedire Y, Pachimatla AG, Petrucci C, et al. Obesity-specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin. Journal of the National Cancer Institute. 2025;117:673\u201384.","journal-title":"Journal of the National Cancer Institute"},{"key":"201_CR28","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1093\/ije\/dyac104","volume":"52","author":"K Bleicher","year":"2023","unstructured":"Bleicher K, Summerhayes R, Baynes S, Swarbrick M, Navin Cristina T, Luc H, et al. Cohort Profile Update: The 45 and Up Study. International journal of epidemiology. 2023;52:e92\u2013e101.","journal-title":"International journal of epidemiology"},{"key":"201_CR29","unstructured":"https:\/\/www.saxinstitute.org.au\/solutions\/45-and-up-study\/use-the-45-and-up-study\/data-and-technical-information\/."},{"key":"201_CR30","unstructured":"https:\/\/www.cancer.nsw.gov.au\/getmedia\/1d6bf5fd-eea3-48a4-b800-f794a1e8495e\/Degree-of-spread-caveat-may-2015.pdf. Available from: https:\/\/www.cancer.nsw.gov.au\/getmedia\/1d6bf5fd-eea3-48a4-b800-f794a1e8495e\/Degree-of-spread-caveat-may-2015.pdf."},{"key":"201_CR31","unstructured":"https:\/\/www.cherel.org.au\/media\/38825\/nsw-cancer-registry-data-dictionary_may2015.pdf. Available from: https:\/\/www.cherel.org.au\/media\/38825\/nsw-cancer-registry-data-dictionary_may2015.pdf."},{"key":"201_CR32","doi-asserted-by":"publisher","first-page":"e0180033","DOI":"10.1371\/journal.pone.0180033","volume":"12","author":"Q Luo","year":"2017","unstructured":"Luo Q, Egger S, Yu XQ, Smith DP, O\u2019Connell DL. Validity of using multiple imputation for \u201cunknown\u201d stage at diagnosis in population-based cancer registry data. PloS one. 2017;12:e0180033.","journal-title":"PloS one"},{"key":"201_CR33","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.canep.2013.09.008","volume":"37","author":"Q Luo","year":"2013","unstructured":"Luo Q, Yu XQ, Cooke-Yarborough C, Smith DP, O\u2019Connell DL. Characteristics of cases with unknown stage prostate cancer in a population-based cancer registry. Cancer epidemiology. 2013;37:813\u20139.","journal-title":"Cancer epidemiology"},{"key":"201_CR34","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2016.16435","volume":"316","author":"DN Kyriacou","year":"2016","unstructured":"Kyriacou DN, Lewis RJ. Confounding by Indication in Clinical Research. Jama. 2016;316:1818\u20139.","journal-title":"Jama"},{"key":"201_CR35","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41416-022-01827-1","volume":"127","author":"V Nair-Shalliker","year":"2022","unstructured":"Nair-Shalliker V, Bang A, Egger S, Yu XQ, Chiam K, Steinberg J, et al. Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study. British journal of cancer. 2022;127:735\u201346.","journal-title":"British journal of cancer"},{"key":"201_CR36","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1158\/1055-9965.EPI-12-1050","volume":"22","author":"X Xue","year":"2013","unstructured":"Xue X, Kim MY, Gaudet MM, Park Y, Heo M, Hollenbeck AR, et al. A comparison of the polytomous logistic regression and joint cox proportional hazards models for evaluating multiple disease subtypes in prospective cohort studies. Cancer epidemiology. biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2013;22:275\u201385.","journal-title":"biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"},{"key":"201_CR37","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s11154-024-09879-9","volume":"25","author":"NK Adjei","year":"2024","unstructured":"Adjei NK, Samkange-Zeeb F, Boakye D, Saleem M, Christianson L, Kebede MM, et al. Ethnic differences in metabolic syndrome in high-income countries: A systematic review and meta-analysis. Reviews in endocrine & metabolic disorders. 2024;25:727\u201350.","journal-title":"Reviews in endocrine & metabolic disorders"},{"key":"201_CR38","doi-asserted-by":"crossref","unstructured":"Raheem E. Missing Data Imputation: A Practical Guide. In: Mitra AK, editor. Statistical Approaches for Epidemiology: From Concept to Application. Cham: Springer International Publishing; 2024. p. 293-316.","DOI":"10.1007\/978-3-031-41784-9_18"},{"key":"201_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.juro.2014.02.005","volume":"192","author":"JC Hu","year":"2014","unstructured":"Hu JC, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, et al. Targeted prostate biopsy in select men for active surveillance: do the Epstein criteria still apply?. The Journal of urology. 2014;192:385\u201390.","journal-title":"The Journal of urology"},{"key":"201_CR40","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/ijc.27414","volume":"131","author":"JK Bassett","year":"2012","unstructured":"Bassett JK, Severi G, Baglietto L, MacInnis RJ, Hoang HN, Hopper JL, et al. Weight change and prostate cancer incidence and mortality. Int J Cancer. 2012;131:1711\u20139.","journal-title":"Int J Cancer"},{"key":"201_CR41","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.annonc.2019.09.007","volume":"31","author":"JM Genkinger","year":"2020","unstructured":"Genkinger JM, Wu K, Wang M, Albanes D, Black A, van den Brandt PA, et al. Measures of body fatness and height in early and mid-to-late adulthood and prostate cancer: risk and mortality in The Pooling Project of Prospective Studies of Diet and Cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2020;31:103\u201314.","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology"},{"key":"201_CR42","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1093\/jnci\/djg009","volume":"95","author":"E Giovannucci","year":"2003","unstructured":"Giovannucci E, Rimm EB, Liu Y, Leitzmann M, Wu K, Stampfer MJ, et al. Body mass index and risk of prostate cancer in U.S. health professionals. Journal of the National Cancer Institute. 2003;95:1240\u20134.","journal-title":"Journal of the National Cancer Institute"},{"key":"201_CR43","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ijc.29842","volume":"138","author":"E M\u00f6ller","year":"2016","unstructured":"M\u00f6ller E, Wilson KM, Batista JL, Mucci LA, B\u00e4lter K, Giovannucci E. Body size across the life course and prostate cancer in the Health Professionals Follow-up Study. International journal of cancer. 2016;138:853\u201365.","journal-title":"International journal of cancer"},{"key":"201_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0876-7","volume":"15","author":"A Perez-Cornago","year":"2017","unstructured":"Perez-Cornago A, Appleby PN, Pischon T, Tsilidis KK, Tj\u00f8nneland A, Olsen A, et al. Tall height and obesity are associated with an increased risk of aggressive prostate cancer: results from the EPIC cohort study. BMC medicine. 2017;15:115.","journal-title":"BMC medicine"},{"key":"201_CR45","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1158\/1055-9965.EPI-08-0342","volume":"17","author":"L Zuccolo","year":"2008","unstructured":"Zuccolo L, Harris R, Gunnell D, Oliver S, Lane JA, Davis M, et al. Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis. Cancer epidemiology. biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008;17:2325\u201336.","journal-title":"biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"},{"key":"201_CR46","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s13679-012-0029-4","volume":"1","author":"C Pelusi","year":"2012","unstructured":"Pelusi C, Pasquali R. The Significance of Low Testosterone Levels in Obese Men. Current Obesity Reports. 2012;1:181\u201390.","journal-title":"Current Obesity Reports"},{"key":"201_CR47","first-page":"1465","volume":"27","author":"S Harrison","year":"2016","unstructured":"Harrison S, Tilling K, Turner EL, Lane JA, Simpkin A, Davis M, et al. Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful? Cancer causes & control. CCC. 2016;27:1465\u201374.","journal-title":"CCC"},{"key":"201_CR48","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1038\/sj.ijo.0801406","volume":"24","author":"N Lima","year":"2000","unstructured":"Lima N, Cavaliere H, Knobel M, Halpern A, Medeiros-Neto G. Decreased androgen levels in massively obese men may be associated with impaired function of the gonadostat. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity. 2000;24:1433\u20137.","journal-title":"International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity"},{"key":"201_CR49","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.mce.2011.12.017","volume":"351","author":"G Williams","year":"2012","unstructured":"Williams G. Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-\u03b1 and GPER signalling. Molecular and cellular endocrinology. 2012;351:269\u201378.","journal-title":"Molecular and cellular endocrinology"},{"key":"201_CR50","first-page":"748","volume":"18","author":"RL Grubb 3rd","year":"2009","unstructured":"Grubb RL 3rd, Black A, Izmirlian G, Hickey TP, Pinsky PF, et al. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate. Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2009;18:748\u201351.","journal-title":"Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"},{"key":"201_CR51","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10552-020-01291-3","volume":"31","author":"S Harrison","year":"2020","unstructured":"Harrison S, Tilling K, Turner EL, Martin RM, Lennon R, Lane JA, et al. Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen. Cancer causes & control : CCC. 2020;31:431\u201349.","journal-title":"Cancer causes & control : CCC"},{"key":"201_CR52","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1158\/1055-9965.EPI-20-1571","volume":"30","author":"K Chiam","year":"2021","unstructured":"Chiam K, Bang A, Patel MI, Nair-Shalliker V, O\u2019Connell DL, Smith DP. Characteristics Associated with the Use of Diagnostic Prostate Biopsy and Biopsy Outcomes in Australian Men. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2021;30:1735\u201343.","journal-title":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"},{"key":"201_CR53","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1016\/j.juro.2009.08.041","volume":"182","author":"S Loeb","year":"2009","unstructured":"Loeb S, Carter HB, Schaeffer EM, Ferrucci L, Kettermann A, Metter EJ. Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging. The Journal of urology. 2009;182:2646\u201351.","journal-title":"The Journal of urology"},{"key":"201_CR54","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1002\/pros.21380","volume":"71","author":"JL Wright","year":"2011","unstructured":"Wright JL, Lin DW, Stanford JL. The effect of demographic and clinical factors on the relationship between BMI and PSA levels. The Prostate. 2011;71:1631\u20137.","journal-title":"The Prostate"},{"key":"201_CR55","doi-asserted-by":"publisher","DOI":"10.1177\/2042018820926000","volume":"11","author":"R Pu","year":"2020","unstructured":"Pu R, Shi D, Gan T, Ren X, Ba Y, Huo Y, et al. Effects of metformin in obesity treatment in different populations: a meta-analysis. Therapeutic advances in endocrinology and metabolism. 2020;11:2042018820926000.","journal-title":"Therapeutic advances in endocrinology and metabolism"},{"key":"201_CR56","doi-asserted-by":"crossref","unstructured":"Liu Y, Zhang Q, Huang X Effect of metformin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from real-world studies. Prostate Cancer and Prostatic Diseases. 2024.","DOI":"10.1038\/s41391-024-00871-7"},{"key":"201_CR57","doi-asserted-by":"publisher","first-page":"e1914689","DOI":"10.1001\/jamanetworkopen.2019.14689","volume":"2","author":"K Beckmann","year":"2019","unstructured":"Beckmann K, Crawley D, Nordstr\u00f6m T, Aly M, Olsson H, Lantz A, et al. Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results. JAMA network open. 2019;2:e1914689.","journal-title":"JAMA network open"},{"key":"201_CR58","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.7314\/APJCP.2014.15.2.1031","volume":"15","author":"DR Pandeya","year":"2014","unstructured":"Pandeya DR, Mittal A, Sathian B, Bhatta B. Role of hyperinsulinemia in increased risk of prostate cancer: a case control study from Kathmandu Valley. Asian Pacific journal of cancer prevention : APJCP. 2014;15:1031\u20133.","journal-title":"Asian Pacific journal of cancer prevention : APJCP"},{"key":"201_CR59","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1158\/1055-9965.EPI-06-1062","volume":"16","author":"NE Allen","year":"2007","unstructured":"Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Rinaldi S, et al. Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Cancer epidemiology. biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2007;16:1121\u20137.","journal-title":"biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"},{"key":"201_CR60","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/jnci\/94.14.1099","volume":"94","author":"JM Chan","year":"2002","unstructured":"Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. Journal of the National Cancer Institute. 2002;94:1099\u2013106.","journal-title":"Journal of the National Cancer Institute"},{"key":"201_CR61","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1158\/1055-9965.EPI-12-0481-T","volume":"21","author":"AJ Price","year":"2012","unstructured":"Price AJ, Allen NE, Appleby PN, Crowe FL, Travis RC, Tipper SJ, et al. Insulin-like growth factor-I concentration and risk of prostate cancer: results from the European Prospective Investigation into Cancer and Nutrition. Cancer epidemiology. biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2012;21:1531\u201341.","journal-title":"biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"},{"key":"201_CR62","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/ije\/dyac124","volume":"52","author":"EL Watts","year":"2023","unstructured":"Watts EL, Perez-Cornago A, Fensom GK, Smith-Byrne K, Noor U, Andrews CD, et al. Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis. International journal of epidemiology. 2023;52:71\u201386.","journal-title":"International journal of epidemiology"},{"key":"201_CR63","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1530\/ERC-12-0250","volume":"20","author":"AA Lubik","year":"2013","unstructured":"Lubik AA, Gunter JH, Hollier BG, Ettinger S, Fazli L, Stylianou N, et al. IGF2 increases de novo steroidogenesis in prostate cancer cells. Endocrine-related cancer. 2013;20:173\u201386.","journal-title":"Endocrine-related cancer"},{"key":"201_CR64","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1210\/en.2013-1925","volume":"155","author":"R Malaguarnera","year":"2014","unstructured":"Malaguarnera R, Sacco A, Morcavallo A, Squatrito S, Migliaccio A, Morrione A, et al. Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling. Endocrinology. 2014;155:1207\u201321.","journal-title":"Endocrinology"},{"key":"201_CR65","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1158\/0008-5472.CAN-20-1281","volume":"80","author":"A Knuppel","year":"2020","unstructured":"Knuppel A, Fensom GK, Watts EL, Gunter MJ, Murphy N, Papier K, et al. Circulating Insulin-like Growth Factor-I Concentrations and Risk of 30 Cancers: Prospective Analyses in UK Biobank. Cancer research. 2020;80:4014\u201321.","journal-title":"Cancer research"},{"key":"201_CR66","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1002\/ijc.32276","volume":"145","author":"EL Watts","year":"2019","unstructured":"Watts EL, Perez-Cornago A, Appleby PN, Albanes D, Ardanaz E, Black A, et al. The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 in a pooled analysis of 16,024 men from 22 studies. International journal of cancer. 2019;145:3244\u201356.","journal-title":"International journal of cancer"},{"key":"201_CR67","doi-asserted-by":"crossref","unstructured":"James R, Dimopoulou O, Martin RM, Perks CM, Kelly C, Mathias L, et al. Could Reducing Body Fatness Reduce the Risk of Aggressive Prostate Cancer via the Insulin Signalling Pathway? A Systematic Review of the Mechanistic Pathway. Metabolites. 2021;11.","DOI":"10.3390\/metabo11110726"},{"key":"201_CR68","doi-asserted-by":"crossref","unstructured":"Birzniece V, Lam T, McLean M, Reddy N, Shahidipour H, Hayden A, et al. Insulin-like growth factor role in determining the anti-cancer effect of metformin: RCT in prostate cancer patients. Endocrine connections. 2022;11.","DOI":"10.1530\/EC-21-0375"}],"container-title":["BJC Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00201-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00201-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00201-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:03:43Z","timestamp":1770131023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00201-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["201"],"URL":"https:\/\/doi.org\/10.1038\/s44276-025-00201-x","relation":{},"ISSN":["2731-9377"],"issn-type":[{"value":"2731-9377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Individuals gave written informed consent to take part in the study, including consent for follow-up through repeated data collection and linkage of their data to population health databases. Ethical approval for the conduct of the 45 and Up Study was provided by the University of New South Wales Human Research Ethics Committee. Ethical approval for the present study was provided by the NSW Population & Health Services Research Ethics Committee (14\/CIPHS\/54).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"2"}}